01 4Jinarc/Jynarque
02 2Jynarque/Jinarc
03 7Samsca
04 2Samsca/Jinarc
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 759
2019 Revenue in Millions : 544
Growth (%) : 40
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 838
2019 Revenue in Millions : 870
Growth (%) : -4
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 777
2020 Revenue in Millions : 804
Growth (%) : 4
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 848
2020 Revenue in Millions : 728
Growth (%) : 26
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 664
2021 Revenue in Millions : 777
Growth (%) : -15
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 1,054
2021 Revenue in Millions : 848
Growth (%) : 24
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 1,224
2022 Revenue in Millions : 1,054
Growth (%) : 32
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 321
2022 Revenue in Millions : 664
Growth (%) : -45
Main Therapeutic Indication : Others
Currency : USD
2014 Revenue in Millions : 36%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 441
2015 Revenue in Millions : 378
Growth (%) : 17
LOOKING FOR A SUPPLIER?